Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk for a much-awaited entry into the world's most populous country that is grappling with increasing rates of obesity and diabetes.

He and his team then compared the diagnoses for hair loss in these patients’ medical records and found that those prescribed semaglutide had a 50% higher risk of being diagnosed with a hair-loss condition compared to those prescribed Contrave. That risk was twice as high for women as for men.